Abstract
Background: With patients referred to emergency departments (EDs) for acute dyspnea, emergency physicians should consider all possible diagnoses and assess patients’ risk stratification. Copeptin has been shown to have prognostic power for subsequent events, such as death and rehospitalization in patients admitted for dyspnea. The aim of this study was to investigate prognostic role of copeptin variations during hospitalization in patients admitted for dyspnea.
Methods: We conducted a prospective, multicentric, observational study in acute dyspneic patients in three ED centers in Italy. Clinical data and copeptin assessments were performed at admission, and at discharge. A 90-day follow-up was performed.
Results: A total of 336 patients were enrolled, and on the basis of final diagnosis distinguished into two groups: acute heart failure and no acute heart failure. Compared to a control group, in all studied population copeptin values at admission resulted in a significantly (p<0.001) higher median (maximum–minimum): 31 (0–905) versus 8 (0–13) pmol/L. Median copeptin value at admission was 42 (0–905) pmol/L in acute heart failure patients and 20 (0–887) pmol/L in no acute heart failure, respectively (p<0.001). In all studied patients and in each group copeptin at admission and discharge showed significant predictive value for 90-day events (p<0.001). Furthermore, in all patients population and in both groups Δ copeptin values from admission to discharge also showed significant predictive value for 90-day events (p<0.001).
Conclusions: In patients admitted for acute dyspnea, admission, discharge and Δ copeptin variations have significant prognostic value from subsequent 90-day death and rehospitalization.
References
1. Parrinello G, Paterna S, Di Pasquale P, Torres D, Fatta A, Mezzero M, et al. The usefulness of bioelectrical impedance analysis in differentiating dyspnea due to decompensated heart failure. J Card Fail 2008;14:676–86.10.1016/j.cardfail.2008.04.005Search in Google Scholar PubMed
2. Gori CS, Magrini L, Travaglino F, Di Somma S. Role of biomarkers in patients with dyspnea. Eur Rev Med Pharmacol Sci 2011;15:229–40.Search in Google Scholar
3. Potocki M, Breidthardt T, Mueller A, Reichlin T, Socrates T, Arenja N, et al. Copeptin and risk stratification in patients with acute dyspnea. Crit Care 2010;14:R213.10.1186/cc9336Search in Google Scholar PubMed PubMed Central
4. Lee DS, Schull MJ, Alter DA, Austin PC, Laupacis A, Chong A, et al. Early deaths in heart failure patients discharged from emergency department: a population based analysis. Circ Heart Fail 2010;3:228–35.10.1161/CIRCHEARTFAILURE.109.885285Search in Google Scholar PubMed
5. Eurlings LW, Sanders-van Wijk S, van Kimmenade R, Osinski A, van Helmond L, Vallinga M, et al. Multimarker strategy for short term risk assessment in patients with dyspnea in the emergency department. J Am Coll Cardiol 2012;60:1668–77.10.1016/j.jacc.2012.06.040Search in Google Scholar PubMed
6. Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013;168:2186–94.10.1016/j.ijcard.2013.01.228Search in Google Scholar PubMed
7. Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, et al. Short term mortality risk in emergency department acute heart failure. Acad Emerg Med 2011;18:947–58.10.1111/j.1553-2712.2011.01150.xSearch in Google Scholar PubMed
8. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010;43:714–9.10.1016/j.clinbiochem.2010.02.002Search in Google Scholar PubMed
9. Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 2012;10:7.10.1186/1741-7015-10-7Search in Google Scholar PubMed PubMed Central
10. Yalta K, Yalta T, Sivri N, Yetkin E. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013;167:1750–9.10.1016/j.ijcard.2012.12.039Search in Google Scholar PubMed
11. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005;95:8B–13B.10.1016/j.amjcard.2005.03.003Search in Google Scholar PubMed
12. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000;11:406–10.10.1016/S1043-2760(00)00304-0Search in Google Scholar
13. Giannopoulos G, Deftereos S, Panagopoulou V, Kossyvakis C, Kaoukis A, Bouras G, et al. Copeptin as a biomarker in cardiac disease. Curr Top Med Chem 2013;13:231–40.10.2174/15680266113139990088Search in Google Scholar PubMed
14. Katan M, Christ Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140:w13101.10.4414/smw.2010.13101Search in Google Scholar PubMed
15. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 2010;56:1712–9.10.1016/j.jacc.2010.05.049Search in Google Scholar PubMed PubMed Central
16. Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145–52.10.1111/j.1365-2362.2007.01762.xSearch in Google Scholar PubMed
17. Urwyler SA, Schuetz P, Fluri F, Morgenthaler NG, Zweifel C, Bergmann A, et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010;41:1564–7.10.1161/STROKEAHA.110.584649Search in Google Scholar PubMed
18. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121:2102–8.10.1161/CIRCULATIONAHA.109.909663Search in Google Scholar PubMed PubMed Central
19. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058–67.10.1378/chest.06-2336Search in Google Scholar PubMed
20. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219–26.10.1097/SHK.0b013e318033e5daSearch in Google Scholar PubMed
21. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012;14:803–69.10.1093/eurjhf/hfs105Search in Google Scholar PubMed
22. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009;116:257–63.10.1042/CS20080140Search in Google Scholar PubMed
23. Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771–8.10.1111/j.1365-2362.2006.01724.xSearch in Google Scholar PubMed
24. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) Study. Circ Heart Fail 2011;4:613–20.10.1161/CIRCHEARTFAILURE.110.960096Search in Google Scholar PubMed
25. Alehagen U, Dahlström U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. J Am Med Assoc 2011;305:2088–95.10.1001/jama.2011.666Search in Google Scholar PubMed
26. Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, Goetze JP, et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail 2012;18:351–8.10.1016/j.cardfail.2012.01.019Search in Google Scholar PubMed
27. Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009;94:123–9.10.1210/jc.2008-1426Search in Google Scholar PubMed
28. Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome. Revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab 2011;96:1506–15.10.1210/jc.2010-2345Search in Google Scholar PubMed
29. Miller WL, Hartman KA, Grill DE, Struck J, Bergmann A, Jaffe AS. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 2012;98:389–94.10.1136/heartjnl-2011-300823Search in Google Scholar PubMed PubMed Central
30. Di Somma S, Magrini L, Pittoni V, Marino R, Mastrantuono A, Ferri E, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care 2010;14:R116.10.1186/cc9067Search in Google Scholar PubMed PubMed Central
©2014 by De Gruyter
